CN106176661B - A kind of saxagliptin or the capsule of its salt and preparation method thereof - Google Patents
A kind of saxagliptin or the capsule of its salt and preparation method thereof Download PDFInfo
- Publication number
- CN106176661B CN106176661B CN201510210522.9A CN201510210522A CN106176661B CN 106176661 B CN106176661 B CN 106176661B CN 201510210522 A CN201510210522 A CN 201510210522A CN 106176661 B CN106176661 B CN 106176661B
- Authority
- CN
- China
- Prior art keywords
- weight
- coating
- blank pellets
- capsule
- saxagliptin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The present invention provides a kind of saxagliptin or the capsule of its salt, which includes Blank Pellets, isolation coat layer, carries medicine coatings, protection coatings and hydroxypropyl methylcellulose capsules shell；Isolation coat layer is coated on Blank Pellets surface, and weight is at least the 1% of Blank Pellets weight；It carries medicine coatings and is covered on isolation coat layer surface, include drug and coating polymer, drug weight is the 1-5% of Blank Pellets, and the weight of coating polymer is the 1-10% of Blank Pellets weight；Protection coatings, which are covered on, carries pack clothing layer surface, and weight is at least the 1% of Blank Pellets weight；Coating material is stomach dissolution type coating powder；Drug is saxagliptin or its salt.The present invention also provides the methods for preparing the capsule.When the present invention has outstanding long and stability and good uniformity of dosage units in hot and humid environment.
Description
Technical field
The present invention relates to a kind of saxagliptin or the capsule of its salt and preparation method thereof, and in particular to has high stability
Saxagliptin or the pharmaceutical preparation of its salt and preparation method thereof.
Technical background
Saxagliptin and its salt are orally active reversible dipeptidyl peptidase-4 (DPP4) inhibitor, for treating 2 types sugar
Urinate the therapeutic agent of disease.Human body discharges insulinotropic hormone GLP-1 after feed, and then inducing pancreatic discharges insulin.GLP is by blood
The DPP4 that slurry neutralizes in intestines capillary endothelial is inactivated.If DPP4 is suppressed, then the inactivation of GLP-1 can be reduced, certainly with stimulation
Pancreas discharges insulin.The characteristics of this insulin releasing mechanism is that insulin is only secreted because responding feed.
But above-mentioned DPP4 inhibitor saxagliptin is unstable compound.Amino on its molecular structure easily with
Cyano reaction, makes saxagliptin form ring amidine.Catabolite ring amidine is typically considered not no therapeutic activity.This cyclisation is anti-
It should can occur in mushy stage.Specifically, when with common preparation process such as wet granulation, rolling or tabletting carries out drug system
When standby, the speed of this intramolecular cyclization can be accelerated, and generate more inactive cis- ring amidines.A large amount of auxiliary material compatibility result
It has been shown that, saxagliptin and common filler and excipient compatibility are also bad, can generate more cyclisation products.This is to preparation
The Solid administration forms of suitable saxagliptin propose great challenge.
In the prior art, although Sha Gelie can be reduced using the method that drug is isolated with excipient is produced tablet
The intramolecular cyclization degree in spit of fland.However, so far, people are but without the storage problem of solution saxagliptin, the storage through the long period
After depositing, the intramolecular cyclization situation of saxagliptin is still serious.Particularly, in the environment of high temperature and humidity, the degree of intramolecular cyclization is more
Obviously, so that being intended to improve the prior art of saxagliptin stability, when facing storage problem, fail to reach desired effect.
In addition, since saxagliptin is under by Pressure stimulation, it is prone to intramolecular cyclization, it is difficult to using complicated preparation technique
Obtain the preferable saxagliptin preparation of the uniformity.Therefore, how to obtain simultaneously the uniformity is good, when having long stability and
Hot and humid environment also has the saxagliptin preparation of better stability, becomes the significant challenge of this field.
Summary of the invention
In view of the shortcomings of the prior art, one of the objects of the present invention is to provide a kind of saxagliptin or the capsule of its salt,
The capsule includes:
1) Blank Pellets；
2) isolation coat layer: being coated on Blank Pellets surface, and weight is at least the 1% of Blank Pellets weight, preferably 2-
5%, pH 1-3；
3) medicine coatings are carried: being covered on isolation coat layer surface, include drug and coating polymer, drug weight is blank
The 1-5% of pellet, the weight of coating polymer are the 1-10%, pH 1-3 of Blank Pellets weight；
4) coatings are protected: being covered on and carries pack clothing layer surface, weight is at least 1%, the pH 1-3 of Blank Pellets weight；
5) hydroxypropyl methylcellulose capsules shell；
The coating polymer for carrying medicine coatings, isolation coat layer and protection coatings are stomach dissolution type coating powder；It is described
Drug is saxagliptin or its salt.
Preferably, the isolation coat layer, load medicine coatings and protection coatings pH are 1.5-1.8.
Inventors have found that saxagliptin free alkali will obtain more fully salification process within the scope of above-mentioned pH, trip
More hydrogen ions are combined from alkali amino, prevent the generation of intramolecular cyclization impurity ring amidine.Under the pH range, good system is being obtained
In the case of the agent uniformity, it also can get good long-time stability and the stability under hot and humid environment.
The Blank Pellets are the microcrystalline cellulose vegetable pill heart, in the minds of the sucrose ball heart, the starch ball heart, microcrystalline cellulose-lactose ball
One kind.
The medicament contg uniformity A+1.8S of the capsule is less than or equal to 3.5.The saxagliptin preparation of the prior art it is equal
Evenness is poor, and reason is that saxagliptin is more sensitive to pressure, and specification is smaller, ordinary preparation technology and tablet packaging technique
The preferable uniformity can not be obtained in the case where guaranteeing stability.The present invention combine to pH largely gropes, and combine coating and
Drug dose is groped, and the excellent saxagliptin pellet of the uniformity is obtained.Meanwhile inventor also has surprisingly found that, by pellet
It is loaded in hydroxypropyl methyl cellulose (HPMC) capsule shells, not only can get very outstanding long-time stability, also have non-
The effect that stability is kept under hot and humid environment of Chang Youxiu.
The long-time stability and the stability problem under hot and humid environment that the present invention not only solves saxagliptin preparation,
Importantly, the uniformity of preparation of the invention is excellent, it is conducive to clinical use, there are huge clinical application potentiality.
Second object of the present invention is to provide the method for the capsule for preparing above-mentioned saxagliptin or its salt, this method step
Suddenly include:
1) preparation of isolated coating liquid: Opadry stomach dissolution type coating powder or EUDRAGIT EPO are poured into rapidly and slightly stirred
In the acid solution mixed, until coating solution, at complete uniform suspending system, solid content is 15-20%, pH 1-3 in coating solution；
2) it carries the preparation of medicine coating solution: saxagliptin or its salt is dissolved in hydrochloric acid solution；Again by coating polymer
Opadry stomach dissolution type coating powder or EUDRAGIT EPO are poured into saxagliptin acid solution, and stirring is until form complete equal
Even mixture, pH 1-3；
3) it protects the preparation of coating solution: Opadry stomach dissolution type coating powder or EUDRAGIT EPO being poured into rapidly and slightly stirred
In the acid solution mixed, carry out until coating solution is coated fluid solid content 15-20%, pH 1-3 at complete uniform suspending system；
4) Blank Pellets are poured into fluidized bed, 45-55 DEG C of inlet air temperature of adjusting, 40-50 DEG C of temperature of charge, power of fan
35-45 Hz, constant current revolution speed 5-15rpm, spray gun pressure 1.5bar-1.9bar are preheated, to temperature of charge reach 40 DEG C-
50 DEG C, when ambient air relative humidity is less than or equal to 50%, using isolated coating liquid packet isolation coat layer, layer weight to be coated reaches
To Blank Pellets weight at least 1% when, when preferably 2-5%, stop coating, it is dry；
5) when the dry air inlet relative air humidity of isolation coat layer is less than or equal to 50%, medicine is contained using medicine coating solution is carried
Coatings, drugloading rate are the 1-5% of Blank Pellets weight, and the weight of coating polymer is the 1-10% of Blank Pellets weight, dry
Carry medicine coatings；
6) carrying the dry air inlet relative air humidity of medicine coatings is less than or equal to 25 DEG C of 50%(environment temperature) when, utilize guarantor
It protects coating solution packet and protects coatings, material weight gain control is the 1-5% of Blank Pellets weight after drying；
7) it is carried out with hydroxypropyl methylcellulose capsules shell filling.
In the operation of step 4), only when sample temperature reaches 40 DEG C -50 DEG C, can guarantee when being sprayed it is dry and
When, otherwise there is pellet adhesion, this will affect the uniformity and stability of preparation.Temperature is excessively high, then reduces coating efficiency.When into
Air temperature is 45-55 DEG C, and temperature of charge is 40-50 DEG C, when blower frequency is 35-45Hz, can get excellent effect.
Ambient air relative humidity is less than 50% in the drying process；Saxagliptin or its salt capsule 's content moisture contain
Amount≤0.5%.Because content excess moisture exists, it will the long-time stability for influencing saxagliptin capsule are especially accelerating
Under the conditions of stability.Meanwhile ambient air relative humidity is excessively high, can also have an impact to coating process.It is big in relative humidity
It when 50%, easily sticks together between pellet, or even the bed that collapses.And when ambient air humidity is less than 50%, drying efficiency is high, pellet
Content can be dried to 0.5% moisture without adhesion, and finally.Greater than 50% humidity, the moisture of pellet will not be down to
0.5% or less.
Preferably, coating solution pH described in step 1)-step 3) is 1.5-1.8.
Inventors have found that saxagliptin free alkali will obtain more fully salification process within the scope of above-mentioned pH, trip
More hydrogen ions are combined from alkali amino, prevent the generation of intramolecular cyclization impurity ring amidine.Under the pH range, good system is being obtained
In the case of the agent uniformity, it also can get good long-time stability and the stability under hot and humid environment
The Blank Pellets are the microcrystalline cellulose vegetable pill heart, in the minds of the sucrose ball heart, the starch ball heart, microcrystalline cellulose-lactose ball
One kind.
The medicament contg uniformity A+1.8S of the capsule is less than or equal to 3.5.
The stomach dissolution type coating powder is Opadry I type, Opadry II type, Opadry HP type, EUDRAGIT EPO
One or more of.
Beneficial effects of the present invention:
1) stability and in high temperature height when the capsule of saxagliptin provided by the invention or its salt has very outstanding long
Stability under wet environment is stored one month at 40 DEG C, and total impurities are also only 0.05%；
2) capsule of saxagliptin provided by the invention or its salt has good uniformity of dosage units, the medicament contg uniformity
A+1.8S is less than or equal to 3.5；
3) preparation method of the invention, preparation process is not harsh, easy to implement, has huge application prospect.
Specific embodiment
The present invention is specifically described below by embodiment, it is necessary to which indicated herein is that following embodiment is only used
It is further detailed in the present invention, should not be understood as limiting the scope of the invention, which is skilled in technique
Some nonessential modifications and adaptations that personnel are made according to foregoing invention content, still fall within protection scope of the present invention.
The preparation of 1 saxagliptin coating micro-pill capsule of embodiment
Prescription:
Blank Pellets (the microcrystalline cellulose vegetable pill heart, producer: Japanese Asahi Chemical Industry, partial size 0.8mm) 400g
Saxagliptin 2.5g
Opadry I type 40g
Preparation process
The preparation of spacer layer coating liquid pours into rapidly Opadry I type in the 0.1N hydrochloric acid of gentle agitation, stirring
40min, to coating solution at complete uniform suspending system.It is coated fluid solid content 15%, being adjusted to pH value is 1.5.
Saxagliptin is dissolved in 0.1N hydrochloric acid, is completely dissolved to raw material, is adjusted to pH by the preparation of drug-loaded layer coating solution
Value is 1.5.Opadry I type coating powder is poured into saxagliptin hydrochloric acid solution again, stirs 40min, forms homogeneous mixture
Afterwards, being adjusted to pH value is 1.5.
Preparation method of the preparation method of protective layer coating solution with spacer layer coating liquid.
Blank Pellets are poured into fluidized bed (Chongqing Seiko), 46 DEG C of inlet air temperature of adjusting, 40 DEG C of temperature of charge, blower function
37 Hz of rate, constant current revolution speed 8rpm, spray gun pressure 1.7bar.It is preheated.
Reach 40 DEG C to temperature of charge, when ambient air relative humidity is less than 50%, starts packet isolation coat layer, wait increase
When weighing to 3%, stop coating, it is dry, calculate material weight gain.
Separation layer is dry, and ambient air relative humidity is less than or equal to 50%.After continue to contain medicine coatings, advised according to drug
Lattice control coating drugloading rate is 3%.Dry drug-loaded layer calculates material weight gain.
Protect the same separation layer of layer process.It is 3% that material weight gain control is calculated after drying.
Intermediate surveys content, filling in HPMC capsule according to pharmaceutical specifications.
The preparation prescription of 2 saxagliptin hydrochloride coating micro-pill capsule of embodiment
Blank Pellets (the sucrose ball heart, Hangzhou height is at biological nutrition technology company, partial size 0.6-0.8mm) 200g
Saxagliptin hydrochloride 5.58g
Isolation coat layer Opadry HP type 6g
Carry medicine coatings Opadry HP type 20g
Protect coatings Opadry HP type 6g
Preparation process
1) Blank Pellets are poured into fluidized bed and is heated to 40 DEG C.
2) the Opadry HP coating solution that different pH value are adjusted according to 1 different batches of table packet isolation coat layer: is injected to sky
White pellet surface forms isolation coat layer.Coating parameter: 50 DEG C of air inlet, 40 DEG C of temperature of charge, ambient air relative humidity is small
In be equal to 50%, 35 Hz of blower frequency, constant current revolution speed 15rpm, spray gun atomizing pressure 1.9bar.2 % of control weight gain.
3) dry separation layer, ambient air relative humidity are less than or equal to 50%, contain medicine coatings: will be by 1 different batches of table
The coating solution of medicament mixed liquor for adjusting certain pH value is injected to isolation coat layer surface, increases weight as 10 %, wherein drug accounts for weight gain
Partial 20%, coating polymer account for the 80% of weight section.
4) packet protection coatings: with the spacer layer coating layer process of step 2.
Survey intermediate pellet content, filling HPMC capsule.
。
* note: for each batch in addition to coating solution pH is different, other technology preparations are all the same.
Upper table shows that the low pH of coating solution facilitates the stabilization of saxagliptin, and the intramolecular cyclization product cis ring miaow of generation is aobvious
Write the product filling less than the direct capsule of powder.The table illustrates simultaneously, when pH is within the scope of 1.5-1.8, obtains the steady of preparation
It is qualitative very outstanding.
The preparation of 3 saxagliptin coating micro-pill capsule of embodiment
Blank Pellets (self-control microcrystalline cellulose-lactose ball heart) 200g
Saxagliptin 5g
Isolation coat layer EUDRAGIT EPO 6g
Carry medicine coatings EUDRAGIT EPO 20g
Protect coatings EUDRAGIT EPO 6g
Preparation process:
1) Blank Pellets are poured into fluidized bed and is heated to 40 DEG C.
2) packet isolation coat layer: the EUDRAGIT EPO coating solution that pH value is 1.6 is injected to Blank Pellets surface and is formed
Isolation coat layer.Coating parameter: inlet air temperature is 45 DEG C, and temperature of charge is 40 DEG C, and ambient air relative humidity is less than or equal to
50%, blower frequency is 45 Hz, constant current revolution speed 15rpm, spray gun atomizing pressure 1.9bar.Control weight gain 1%.
3) dry separation layer, ambient air relative humidity are less than or equal to 50%, contain medicine coatings: the medicine for being 1.6 by pH value
Object coating solution mixed liquor is injected to isolation coat layer surface, is 2% wait increase weight, and wherein drug weight is the 1% of pellet weight, coating
Polymer weight is the 1% of pellet weight.
4) packet protection coatings: coating weight gain amount and technique are consistent under step 3) separation layer item.
5) intermediate pellet content, filling HPMC capsule are surveyed.
。
The preparation of 4 saxagliptin coating micro-pill capsule of embodiment
Blank Pellets (the starch ball heart, partial size 0.8mm) 200g
Saxagliptin 5g
Isolation coat layer Opadry II type 10g
Carry medicine coatings Opadry II type 30g
Protect coatings Opadry II type 10g
Preparation process:
1) Blank Pellets are poured into fluidized bed and is heated to 40 DEG C.
2) the Opadry II type coating solution that the solid content that pH value is 1.8 is 15% packet isolation coat layer: is injected to blank
Pellet surface forms isolation coat layer.Coating parameter: 50 DEG C of air inlet, 42 DEG C of temperature of charge, 40 Hz of blower frequency, constant flow pump turns
Speed 10 rpm, 1.7 bar of spray gun atomizing pressure are 40 DEG C to temperature of charge, and ambient air relative humidity is less than or equal to 50%, into
Row coating.Control weight gain 5%.
3) medicine coatings are contained after dry isolation coat layer: by the coating solution of medicament mixed liquor that pH value is 1.8 be injected to every
It is 10% wait increase weight from coating layer surface, wherein drug weight is the 2% of pellet weight, and coating polymer weight is pellet weight
8%.Coating parameter is the same as isolation coat layer process.
4) packet protective layer: coating weight gain amount and technique are consistent under step 2 isolation coat layer item.
5) intermediate pellet content is surveyed, respectively filling HPMC capsule and gelatine capsule.
。
It is unstable to will lead to sample using the filling content of gelatine capsule.Stablized using the filling contents samples of HPMC capsule
Surprising outstanding of property.
The preparation of 5 saxagliptin coating micro-pill capsule of embodiment
Blank Pellets (the microcrystalline cellulose vegetable pill heart, Japanese Asahi Chemical Industry, partial size 1.0mm) 625g
Saxagliptin 32g
Opadry II type 130g
HPMC capsule shells
Preparation process:
1) Blank Pellets are poured into fluidized bed and is heated to 40 DEG C.
2) the Opadry II type coating solution that the solid content that pH value is 1.5 is 15% packet isolation coat layer: is passed through into fluidized bed
Top spray is sprayed into pelletizes into fluidized bed.Technological parameter: top spray, 50 DEG C of temperature of charge, 45 DEG C of inlet air temperature, hydrojet revolving speed 10
Rpm enters the wind 45 Hz of frequency, 10 rpm of constant current revolution speed, 1.7 bar of spray gun atomizing pressure, is 40 DEG C to temperature of charge, environment
Relative air humidity be less than or equal to 50%, when be coated.Dry 10min, control weight gain 3%.
3) medicine coatings are contained: being that 1.5 coating solution of medicament mixed liquors are injected to isolation coat layer surface by pH value, wait increase weight
It is 15%, wherein drug weight is the 5% of pellet weight, and coating polymer weight is the 10% of pellet weight, and art for coating is the same as isolation
It is coated layer process.Dry 10min.
4) packet protection coatings: weight gain and technique are the same as isolation coat layer.Border relative air humidity is less than or equal to 50%, drying
Ring is to moisture less than 0.5%.
5) off-white color saxagliptin coating powder (particle) is obtained, HPMC capsule is filled after middle control.
。
Claims (10)
1. the capsule of a kind of saxagliptin or its salt, which is characterized in that the capsule includes:
1) Blank Pellets；
2) isolation coat layer: being coated on Blank Pellets surface, and weight is at least 1 % of Blank Pellets weight；
3) medicine coatings are carried: being covered on isolation coat layer surface, include drug and coating polymer, drug weight is Blank Pellets
1-5 %, the weight of coating polymer is the 1-10% of Blank Pellets weight；
4) coatings are protected: being covered on and carries pack clothing layer surface, weight is at least the 1% of Blank Pellets weight；
5) hydroxypropyl methylcellulose capsules shell:
The coating polymer for carrying medicine coatings, isolation coat layer and protection coatings are stomach dissolution type coating powder；The drug
For saxagliptin or its salt；
The isolation coat layer carries medicine coatings and protects the pH of coatings for 1,5-1 8.
2. the capsule according to claim 1, which is characterized in that isolation coat layer: being coated on Blank Pellets surface, weight
Amount is the 2-5 % of Blank Pellets weight.
3. the capsule according to claim 1, which is characterized in that the Blank Pellets are the microcrystalline cellulose vegetable pill heart, sucrose
One of the ball heart, the starch ball heart, microcrystalline cellulose-lactose ball heart.
4. the capsule according to claim 1, which is characterized in that+1.8 S of medicament contg uniformity A of the capsule
Less than or equal to 3.5.
5. the method for preparing capsule as described in claim 1, which is characterized in that the method comprises the following steps: 1) every
Preparation from coating solution: stomach dissolution type coating powder being poured into rapidly in the acid solution of gentle agitation, until coating solution is at complete
Uniform suspending system, solid content is 15-20 % in coating solution；
2) it carries the preparation of medicine coating solution: saxagliptin or its salt is dissolved in acid solution；Again by coating polymer stomach dissolution type
Coating powder pours into saxagliptin hydrochloric acid solution, and stirring is until form complete homogeneous mixture；
3) it protects the preparation of coating solution: stomach dissolution type coating powder being poured into rapidly in the acid solution of gentle agitation, carried out until packet
Clothing liquid is coated fluid solid content 15-20 % at complete uniform suspending system；
4) Blank Pellets are poured into fluidized bed, 45-55 DEG C of inlet air temperature of adjusting, 40-50 DEG C of temperature of charge, power of fan
35-45Hz, constant current revolution speed 5-15rpm, spray gun pressure 1.5bar -1.9bar are preheated, are reached to temperature of charge
40 DEG C -50 DEG C, ambient air relative humidity is less than or equal to 50%, using isolated coating liquid packet isolation coat layer, to coatings weight
When amount reaches at least the 1% of Blank Pellets weight, stop coating, it is dry；
5) isolation coat layer is dry, and ambient air relative humidity is less than or equal to 50 %, contains pack clothing using medicine coating solution is carried
Layer, drugloading rate are the 1-5% of Blank Pellets weight, and the weight of coating polymer is the 1-10% of Blank Pellets weight, dry
Carry medicine coatings；
6) it is dry that medicine coatings are carried, ambient air relative humidity utilizes protection coating solution packet protection coating less than or equal to 50%
Layer, material weight gain control is the 1-5% of Blank Pellets weight after drying；
7) it is carried out with hydroxypropyl methylcellulose capsules shell filling；
The pH of coating solution described in step 1- step 3) is 1.5-1.8.
6. the method according to claim 5, which is characterized in that isolated coating liquid packet isolation coat layer is utilized, wait be coated
Layer weight reaches the 2-5% of Blank Pellets weight.
7. the method according to claim 5, which is characterized in that the Blank Pellets are the microcrystalline cellulose vegetable pill heart, sucrose
One of the ball heart, the starch ball heart, microcrystalline cellulose-lactose ball heart.
8. the method according to claim 5, which is characterized in that the medicament contg uniformity A+1.8S of the capsule
Less than or equal to 3.5.
9. the method according to claim 5, which is characterized in that saxagliptin or its salt capsule 's content moisture content are total
≤ 0.5%.
10. the method according to claim 5, which is characterized in that the stomach dissolution type coating powder be I type of Opadry,
II type of Opadry, Opadry HP type, the one or more of EUDRAG IT EPO.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510210522.9A CN106176661B (en) | 2015-04-29 | 2015-04-29 | A kind of saxagliptin or the capsule of its salt and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510210522.9A CN106176661B (en) | 2015-04-29 | 2015-04-29 | A kind of saxagliptin or the capsule of its salt and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106176661A CN106176661A (en) | 2016-12-07 |
| CN106176661B true CN106176661B (en) | 2019-02-01 |
Family
ID=57458144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510210522.9A Active CN106176661B (en) | 2015-04-29 | 2015-04-29 | A kind of saxagliptin or the capsule of its salt and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176661B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1988891A (en) * | 2004-05-28 | 2007-06-27 | 布里斯托尔-迈尔斯斯奎布公司 | Coated tablet formulation and method |
| CN101623275A (en) * | 2009-03-16 | 2010-01-13 | 江苏天一时制药有限公司 | Capsule containing candesartan cilexetil and preparation method thereof |
| WO2013106526A1 (en) * | 2012-01-10 | 2013-07-18 | Teva Pharmaceutical Industries Ltd. | Saxagliptin parmaceutical formulations |
-
2015
- 2015-04-29 CN CN201510210522.9A patent/CN106176661B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1988891A (en) * | 2004-05-28 | 2007-06-27 | 布里斯托尔-迈尔斯斯奎布公司 | Coated tablet formulation and method |
| CN101623275A (en) * | 2009-03-16 | 2010-01-13 | 江苏天一时制药有限公司 | Capsule containing candesartan cilexetil and preparation method thereof |
| WO2013106526A1 (en) * | 2012-01-10 | 2013-07-18 | Teva Pharmaceutical Industries Ltd. | Saxagliptin parmaceutical formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106176661A (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1195499C (en) | Enteric coated pharmaceutical tablet and method of manufacturing | |
| CN105030725B (en) | Vonoprazan fumarate enteric-coated composition and preparation method thereof | |
| CN104473905A (en) | Trimetazidine hydrochloride sustained-release capsule and preparation method thereof | |
| CN105456223B (en) | Mesalazine sustained release pellet and preparation method thereof and Mesalazine spansule | |
| CN104208039B (en) | Naproxen esomeprazole enteric preparation and preparation method thereof | |
| CN104042575A (en) | Preparation method for doxycycline modified release pellet and preparation | |
| CN107432936A (en) | A kind of purposes of modification of chitosan and the nano-complex comprising the modification of chitosan | |
| CN104434846A (en) | Metformin hydrochloride enteric-coated sustained-release pellet and preparation method thereof | |
| CN106176661B (en) | A kind of saxagliptin or the capsule of its salt and preparation method thereof | |
| CN102824316B (en) | Esomeprazole medicated pellet and preparing method thereof | |
| CN112220775A (en) | Preparation intermediate granule containing calcium carbonate and vitamin D3 and preparation method thereof | |
| CN102631327B (en) | Enteric coated omeprazole pellet and preparation method thereof | |
| CN111214456A (en) | Voriconazole dry suspension and preparation method thereof | |
| CN102793658A (en) | Matrix-type preparation containing mycophenolic acid or mycophenolic acid salt and coated tablet thereof | |
| CN105434398A (en) | Rabeprazole enteric-coated micro pellet, and preparation method thereof | |
| CN105616376B (en) | Composition and preparation method containing magnesium isoglycyrrhetate medicine | |
| CN104645322B (en) | A kind of phosphoesterases complex enteric coatel tablets and its preparation method and application | |
| CN106692094A (en) | Rolapitant medicine oral preparation and preparation method thereof | |
| CN108125930B (en) | Metformin hydrochloride sustained-release capsule composition and preparation method thereof | |
| CN102416007B (en) | Metformin hydrochloride enteric-coated capsules | |
| CN106806353A (en) | Ailamode spansule and preparation method thereof | |
| CN102068418B (en) | Sofalcone sustained-release pellet capsule preparation and preparation method thereof | |
| CN105168177B (en) | Saxagliptin capsule and preparation method thereof | |
| CN114392241B (en) | Ripide Wei Linpian and preparation method thereof | |
| CN110403918A (en) | A kind of hydrochloric acid roxatidine acetate spansule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |